keyword
MENU ▼
Read by QxMD icon Read
search

infliximab serum

keyword
https://www.readbyqxmd.com/read/27904147/penile-constitutive-nitric-oxide-synthase-expression-in-rats-exposed-to-unpredictable-chronic-mild-stress-role-of-inflammation
#1
T D Şahin, Y Yazır, T Utkan, S S Göçmez, D Bayramgürler
Chronic psychological stress cause erectile dysfunction (ED). Considering recent evidence that tumor necrosis factor-α (TNF-α) levels are increased in serum of patients with ED, the present study investigated the effects of infliximab (a TNF-α blocker) on endothelial nitric oxide synthase (eNOS) and neuronal NOS (nNOS) immunoreactivity of rat penile corpus cavernosum in unpredictable chronic mild stress (UCMS). Male adult rats were randomly divided into three groups (n=8 per group): Control, UCMS and UCMS+infliximab...
December 1, 2016: International Journal of Impotence Research
https://www.readbyqxmd.com/read/27894157/relationship-between-serum-infliximab-concentrations-and-risk-of-infections-in-patients-treated-for-spondyloarthritis
#2
Theodora Bejan-Angoulvant, David Ternant, Fadela Daoued, Frédéric Medina, Louis Bernard, Saloua Mammou, Gilles Paintaud, Denis Mulleman
OBJECTIVE: Tumor necrosis factor inhibitors are effective in reducing inflammation in rheumatic diseases but increase the risk of infections. This study was undertaken to investigate the relationship between the trough serum concentration of infliximab (IFX) and the risk of a first infection episode. METHODS: We retrospectively included all patients who started IFX treatment for an approved indication in our department. Patients were followed up based on recommended IFX infusion schedules...
November 28, 2016: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/27882586/efficacy-and-safety-of-dose-escalation-of-infliximab-therapy-in-japanese-patients-with-psoriasis-results-of-the-spread-study
#3
Hideshi Torii, Masayuki Nakano, Toshiro Yano, Kazuoki Kondo, Hidemi Nakagawa
Although infliximab is approved for psoriasis, its efficacy is reduced over time in some patients. The aim of this phase III trial is to evaluate efficacy and safety of infliximab dose escalation in Japanese psoriasis patients with loss of efficacy to standard-dose therapy. Patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis or psoriatic erythroderma who showed loss of efficacy to standard-dose therapy received infliximab dose escalation (10 mg/kg every 8 weeks) from weeks 0 to 32. Loss of efficacy was defined as not maintaining 50% reduction in the Psoriasis Area and Severity Index (PASI 50) after achieving PASI 75...
November 24, 2016: Journal of Dermatology
https://www.readbyqxmd.com/read/27873119/validation-of-a-drug-resistant-anti-adalimumab-antibody-assay-to-monitor-immunogenicity-in-the-presence-of-high-concentrations-of-adalimumab
#4
Sumin Bian, Marc Ferrante, Ann Gils
With respect to patient safety and long-term efficacy, immunogenicity of therapeutic antibodies remains an important issue. Pre-treatment of samples using either higher temperature or acidification in order to separate drug/anti-drug antibody complexes has been implemented in the traditional bridging assay and an in-house-developed affinity capture elution assay but only a limited drug tolerance was obtained. In this study, we aim to apply a drug-resistant anti-drug antibody assay to adalimumab through a combination of adalimumab/anti-adalimumab antibody complex precipitation and acid dissociation...
November 21, 2016: AAPS Journal
https://www.readbyqxmd.com/read/27853420/reducing-peripheral-inflammation-with-infliximab-reduces-neuroinflammation-and-improves-cognition-in-rats-with-hepatic-encephalopathy
#5
Sherry Dadsetan, Tiziano Balzano, Jerónimo Forteza, Andrea Cabrera-Pastor, Lucas Taoro-Gonzalez, Vicente Hernandez-Rabaza, Sara Gil-Perotín, Laura Cubas-Núñez, José-Manuel García-Verdugo, Ana Agusti, Marta Llansola, Vicente Felipo
Inflammation contributes to cognitive impairment in patients with hepatic encephalopathy (HE). However, the process by which peripheral inflammation results in cognitive impairment remains unclear. In animal models, neuroinflammation and altered neurotransmission mediate cognitive impairment. Taking into account these data, we hypothesized that in rats with HE: (1) peripheral inflammation is a main contributor to neuroinflammation; (2) neuroinflammation in hippocampus impairs spatial learning by altering AMPA and/or NMDA receptors membrane expression; (3) reducing peripheral inflammation with infliximab (anti-TNF-a) would improve spatial learning; (4) this would be associated with reduced neuroinflammation and normalization of the membrane expression of glutamate receptors...
2016: Frontiers in Molecular Neuroscience
https://www.readbyqxmd.com/read/27845027/clinical-effectiveness-and-cost-effectiveness-of-use-of-therapeutic-monitoring-of-tumour-necrosis-factor-alpha-tnf-%C3%AE-inhibitors-lisa-tracker%C3%A2-enzyme-linked-immunosorbent-assay-elisa-kits-tnf-%C3%AE-blocker-elisa-kits-and-promonitor%C3%A2-elisa-kits-versus-standard-care
#6
Karoline Freeman, Martin Connock, Peter Auguste, Sian Taylor-Phillips, Hema Mistry, Deepson Shyangdan, Rachel Court, Ramesh Arasaradnam, Paul Sutcliffe, Aileen Clarke
BACKGROUND AND OBJECTIVES: Systematic reviews and economic modelling of clinical effectiveness and cost-effectiveness of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [using LISA-TRACKER(®) enzyme-linked immunosorbent assay (ELISA) kits (Theradiag, Marne La Vallee, France, or Alpha Laboratories, Heriot, UK), TNF-α-Blocker ELISA kits (Immundiagnostik AG, Bensheim, Germany) and Promonitor(®) ELISA kits (Proteomika, Progenika Biopharma, Bizkaia, Spain)] versus standard care for Crohn's disease (CD)...
November 2016: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/27821943/green-tea-and-exercise-interventions-as-nondrug-remedies-in-geriatric-patients-with-rheumatoid-arthritis
#7
Ahmad H Alghadir, Sami A Gabr, Einas S Al-Eisa
This study aimed to evaluate the effects of green tea and supervised exercise training interventions on improvement of disease activity and bone metabolism markers in rheumatoid arthritis patients. [Subjects and Methods] One-hundred and twenty subjects who had a mean age of (60.7 ± 2.53 years) and had been diagnosed with rheumatoid arthritis at least ten years previously were randomly included in this study. Patients were treated with infliximab, green tea, or a supervised exercise program for six months...
October 2016: Journal of Physical Therapy Science
https://www.readbyqxmd.com/read/27800198/a-case-report-of-neurosarcoidosis-presenting-as-a-lymphoma-mimic
#8
Gurcharanjeet Kaur, Lauren Cameron, Olga Syritsyna, Patricia Coyle, Agnes Kowalska
Objective. To describe a unique presentation of neurosarcoidosis. Background. Central nervous system involvement is rare in sarcoidosis. Sarcoidosis can be severe and can be mistaken for systemic lymphoma. Case Description. A 55-year-old right-handed white male with past medical history of obstructive sleep apnea, Raynaud's disease, and Hashimoto's thyroiditis was noted to have cognitive decline over a duration of few weeks and 20 lb weight loss. His neurologic exam (including cranial nerves) was normal except for five-minute recall...
2016: Case Reports in Neurological Medicine
https://www.readbyqxmd.com/read/27781498/infliximab-therapy-reverses-the-increase-of-allograft-inflammatory-factor-1-in-serum-and-colonic-mucosa-of-rats-with-inflammatory-bowel-disease
#9
Irene D Román, David Cano-Martínez, María Val T Lobo, María Dolores Fernández-Moreno, Borja Hernández-Breijo, Silvia Sacristán, Patricia Sanmartín-Salinas, Jorge Monserrat, Javier P Gisbert, Luis G Guijarro
: Objetive: Our purpose was to study the molecular basis of infliximab (IFX) effect on colon mucosa in a colitis model and to identify new biomarkers of mucosal healing. METHODS: Healthy rats and rats which were subjected to experimental colitis induced by dextran sulphate sodium, with or without IFX treatment (in the short- and long-term), were studied along with forty-seven IBD patients. Colon mucosal integrity by Periodic Acid Schiff staining, intestinal damage by immunohistochemistry (proliferating cell nuclear antigen, β-catenin, E-cadherin, phosphotyrosine, p-p38, allograft inflammatory factor-1 (AIF-1) and colonic mucosal apoptosis by TUNEL staining were evaluated in rats...
October 26, 2016: Biomarkers: Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals
https://www.readbyqxmd.com/read/27778459/infliximab-is-equivalently-suppressing-oxidative-stress-compared-to-tocilizumab-among-well-controlled-patients-with-rheumatoid-arthritis
#10
Kazuha Kizaki, Fumiharu Yamashita, Tomoya Hayashi, Noboru Funakoshi
AIM: This study was designed to investigate which biological agent, infliximab or tocilizumab, would more intensively keep suppressing oxidative stress among well-controlled patients as C-reactive protein (CRP) levels normalized in rheumatoid arthritis (RA). In addition, it was intended to clarify indicative factors of oxidative stress among well-controlled patients with RA. METHODS: We recruited 61 well-controlled (CRP < 0.3 mg/dL within normal ranges) patients with RA using biological agents (infliximab n = 33; tocilizumab n = 28), active RA patients with CRP > 1...
October 24, 2016: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/27762509/analytical-and-clinical-evaluation-of-an-immunoassay-for-estimating-immunogenicity-of-infliximab-and-etanercept-in-indian-population
#11
Canna Ghia, Shashank Akerkar, Shailaja Sabnis, Urk Rao, Gautam Rambhad
BACKGROUND / OBJECTIVES: Biologic anti-TNFs in India have improved the patient management. Significant proportions of patients lose response over time or do not respond. Possible explanations are suboptimal trough anti-TNFa concentrations or antibodies to anti-TNFs. The aim of this project was to set up and standardize an independent laboratory to test immunogenicity of anti-TNF biologics (infliximab and etanercept). METHODS: Three rheumatologists piloted this project approved by independent ethics committee and carried out in compliance with ICH/GCP guidelines...
September 2016: Journal of the Association of Physicians of India
https://www.readbyqxmd.com/read/27747509/early-prognostic-factors-associated-with-the-efficacy-of-infliximab-treatment-for-patients-with-rheumatoid-arthritis-with-inadequate-response-to-methotrexate
#12
Satoko Hayashi, Katsuya Suzuki, Keiko Yoshimoto, Masaru Takeshita, Takahiko Kurasawa, Kunihiro Yamaoka, Tsutomu Takeuchi
INTRODUCTION: Early prognostic factors for the clinical response in patients with rheumatoid arthritis (RA) after 1 year of treatment with infliximab (IFX) as part of routine clinical practice were investigated. METHODS: Thirty-five patients with RA with an inadequate response to methotrexate were enrolled and administered IFX (3-9 mg/kg, every 4-8 weeks). Serum trough levels of IFX and levels of 9 cytokines were measured at baseline and at 3, 6 months, and 1 year...
June 2016: Rheumatology and Therapy
https://www.readbyqxmd.com/read/27739008/pharmacokinetic-dashboard-recommended-dosing-is-different-than-standard-of-care-dosing-in-infliximab-treated-pediatric-ibd-patients
#13
Marla C Dubinsky, Becky L Phan, Namita Singh, Shervin Rabizadeh, Diane R Mould
Standard of care (SOC; combination of 5-10 mg/kg and an interval every 6-8 weeks) dosing of infliximab (IFX) is associated with significant loss of response. Dashboards using covariates that influence IFX pharmacokinetics (PK) may be a more precise way of optimizing anti-TNF dosing. We tested a prototype dashboard to compare forecasted dosing regimens with actual administered regimens and SOC. Fifty IBD patients completing IFX induction were monitored during maintenance (weeks 14-54). Clinical and laboratory data were collected at each infusion; serum was analyzed for IFX concentrations and anti-drug antibodies (ADA) at weeks 14 and 54 (Prometheus Labs, San Diego)...
October 13, 2016: AAPS Journal
https://www.readbyqxmd.com/read/27702827/association-of-induction-infliximab-levels-with-clinical-response-in-perianal-crohn-s-disease
#14
Yana Davidov, Bella Ungar, Haggai Bar-Yoseph, Dan Carter, Ola Haj-Natour, Miri Yavzori, Yehuda Chowers, Rami Eliakim, Shomron Ben-Horin, Uri Kopylov
BACKGROUND: The association of infliximab [IFX] trough levels with clinical and endoscopic outcomes in inflammatory bowel disease is well established. However, there is scarce data regarding the association of perianal fistula response with IFX. The aim of this study was to establish whether early induction infliximab levels and anti-infliximab antibodies [ATIs] are associated with perianal fistula response. METHODS: Consecutive CD patients with perianal fistulae that were treated with IFX between 2008 and 2016 were included in the study...
October 4, 2016: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/27664854/standardization-of-the-homogeneous-mobility-shift-assay-protocol-for-evaluation-of-anti-infliximab-antibodies-application-of-the-method-to-crohn-s-disease-patients-treated-with-infliximab
#15
B Hernández-Breijo, M Chaparro, D Cano-Martínez, I Guerra, M Iborra, J L Cabriada, L Bujanda, C Taxonera, V García-Sánchez, I Marín-Jiménez, M Barreiro-de Acosta, I Vera, M D Martín-Arranz, F Mesonero, L Sempere, F Gomollón, J Hinojosa, J P Gisbert, L G Guijarro
BACKGROUND: The availability of a quantitative method to measure anti-infliximab (IFX) antibodies (ATI) would facilitate the implementation of therapeutic drug monitoring in clinical decision-making. Our aim was to standardize the homogeneous mobility shift assay (HMSA) used in the measure of ATI levels. METHODS: In this prospective longitudinal multicenter study, 50 IFX-treated Crohn's disease (CD) patients were followed up for 54weeks. During this period 360 human serum samples were analysed...
December 15, 2016: Biochemical Pharmacology
https://www.readbyqxmd.com/read/27660934/safety-of-corticosteroid-treatment-in-rheumatologic-patients-with-markers-of-hepatitis-b-viral-infection-pilot-evaluation-study
#16
Yolanda Braun-Moscovici, Marius Braun, Tarek Saadi, Doron Markovits, Menahem A Nahir, Alexandra Balbir-Gurman
BACKGROUND: Immunosuppressive agents may induce hepatitis B flares. The minimal corticosteroid dose and duration of therapy leading to HBV reactivation is unknown. OBJECTIVE: To assess whether short-term corticosteroid therapy for rheumatologic diseases induces HBV reactivation. METHODS: The records of all HBsAg or HBcore antibodies positive, anti-HBs negative patients who were hospitalized in the rheumatology department during 2001-2014 and treated with corticosteroids were reviewed...
October 2016: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
https://www.readbyqxmd.com/read/27643491/immunogenicity-and-lupus-like-autoantibody-production-can-be-linked-to-each-other-along-with-type-i-interferon-production-in-patients-with-rheumatoid-arthritis-treated-with-infliximab-a-retrospective-study-of-a-single-center-cohort
#17
Yuki Ishikawa, Takao Fujii, Seiko Kondo Ishikawa, Naoichiro Yukawa, Motomu Hashimoto, Moritoshi Furu, Hiromu Ito, Koichiro Ohmura, Tsuneyo Mimori
Besides anti-drug antibodies, anti-nuclear antibodies and anti-DNA antibodies are often induced in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors. We examined the association between immunogenicity, autoantibody production, and serum cytokine profiles in patients with rheumatoid arthritis treated with infliximab. Japanese patients with rheumatoid arthritis (n = 57) were retrospectively examined. Serum trough levels of infliximab, anti-drug antibody, anti-nuclear antibody, and anti-DNA (Farr), anti-single-stranded DNA and anti-double-stranded DNA antibodies were measured...
2016: PloS One
https://www.readbyqxmd.com/read/27628422/identification-of-pathway-specific-serum-biomarkers-of-response-to-glucocorticoid-and-infliximab-treatment-in-children-with-inflammatory-bowel-disease
#18
Christopher R Heier, Alyson A Fiorillo, Ellen Chaisson, Heather Gordish-Dressman, Yetrib Hathout, Jesse M Damsker, Eric P Hoffman, Laurie S Conklin
OBJECTIVE: Serum biomarkers may serve to predict early response to therapy, identify relapse, and facilitate drug development in inflammatory bowel disease (IBD). Biomarkers are particularly important in children, in whom achieving early remission and minimizing procedures are especially beneficial. METHODS: We profiled protein and micro RNA (miRNA) in serum from patients pre- and post-therapy, to identify molecular markers of pharmacodynamic effect. Serum was obtained from children with IBD before and after treatment with either corticosteroids (prednisone; n=12) or anti-tumor necrosis factor-α biologic (infliximab; n=7)...
2016: Clinical and Translational Gastroenterology
https://www.readbyqxmd.com/read/27607335/preoperative-anti-tumor-necrosis-factor-therapy-in-patients-with-ulcerative-colitis-is-not-associated-with-an-increased-risk-of-infectious-and-noninfectious-complications-after-ileal-pouch-anal-anastomosis
#19
Eran Zittan, Raquel Milgrom, Grace W Ma, Nathalie Wong-Chong, Brenda OʼConnor, Robin S McLeod, Helen M MacRae, Gordon R Greenberg, Geoffrey C Nguyen, Kenneth Croitoru, A Hillary Steinhart, Zane Cohen, Mark S Silverberg
BACKGROUND: There are conflicting data regarding the effect of previous exposure to anti-tumor necrosis factor (anti-TNF) therapy on complication rates after pelvic pouch surgery for patients with ulcerative colitis (UC). In particular, there is concern surrounding the rates of pouch leaks and infectious complications, including pelvic abscesses, in anti-TNF-treated subjects who require ileal pouch-anal anastomosis (IPAA) surgery. METHODS: A retrospective study was performed in UC subjects who underwent IPAA between 2002 and 2013...
October 2016: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/27600137/comparisons-of-serum-infliximab-and-antibodies-to-infliximab-tests-used-in-inflammatory-bowel-disease-clinical-trials-of-remicade%C3%A2
#20
Joseph C Marini, Jocelyn Sendecki, Freddy Cornillie, John W Popp, Shawn Black, Marion Blank, Ann Gils, Thomas Van Stappen, Dörte Hamann, Theo Rispens, Lina Thérien, Kelly Chun, Gopi Shankar
Monitoring infliximab (IFX) concentrations and antibodies-to-IFX (ATI) titers during inflammatory bowel disease treatment may allow more informed decisions in assessing exposure/response and determining appropriate dosing. To aid in interpreting results from different commercial tests in the context of Janssen's published Remicade® results, the reliability of Janssen's IFX and ATI assays was compared with commercial assays from KU Leuven, Sanquin, Dynacare, and LabCorp. Test results were independently reported to Janssen...
September 6, 2016: AAPS Journal
keyword
keyword
43807
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"